Exosomes News and Research

RSS

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

Diagnostic Hybrids, a leading developer of in vitro diagnostic fluorescent staining kits and cell culture products, announces the U.S. Food and Drug Administration (FDA) (510k) clearance of its D3 FastPointTM L-DFATM Influenza A/ Influenza B Virus Identification Kit, which allows for the identification of influenza A virus and influenza B virus from a patient’s specimen in under 30 minutes.

28 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

Aethlon Medical establishes ESI as a wholly owned subsidiary

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that it has established Exosome Sciences, Inc. (ESI) as a wholly owned subsidiary of the Company.

23 Oct 2009

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial.

22 Oct 2009

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Novavax, Inc. (Nasdaq: NVAX) announced today that it has initiated a two-stage clinical study of its virus-like-particle (VLP) H1N1 influenza vaccine in Mexico in collaboration with Avimex Laboratories (Avimex) and GE Healthcare.

20 Oct 2009

Bio-Bridge Science receives business license for Bio-Bridge JRS Biosciences (Beijing)

Bio-Bridge Science, Inc., a biotechnology company engaged in the commercial development of vaccines and vaccine-related products announced today that the Company received a business license from the Beijing Administration for Industry and Commerce of the People’s Republic of China (“PRC”) indicating approval of the formation of Bio-Bridge JRS Biosciences (Beijing) Co., Ltd. (“Bio-Bridge JRS”).

20 Oct 2009

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Baxter International Inc. today reported solid financial results for the third quarter of 2009, and provided its fourth quarter and updated full-year 2009 financial outlook.

From Baxter International Inc. 15 Oct 2009

Advanced Projects Group and Cellectricon collaborate to produce the Dynaflow HT patch clamp equipment system

The Automation Partnership (TAP), a world leading supplier of innovative automation for life science applications today announced its Advanced Projects Group, has successfully collaborated with Cellectricon, the Swedish provider of innovative screening solutions for drug discovery, to produce fully automated high throughput patch clamp equipment known as the Dynaflow®HT System.

From Cellectricon 14 Oct 2009

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

14 Oct 2009

Researchers discover compounds that show promise as novel treatments for AIDS

While studying an HIV protein that plays an essential role in AIDS progression, researchers at the University of Pittsburgh School of Medicine have discovered compounds that show promise as novel treatments for the disease.

14 Oct 2009

International Stem Cell launches human cell culture products into commercial research markets

International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs.

14 Oct 2009

European Patent Office announces intention to grant patent for Phyton Biotech's methods of producing taxanes

Phyton Biotech GmbH, a world leader in plant cell culture technology, reports that the European Patent Office has announced its intention to grant a European patent to Phyton covering methods of producing taxanes such as paclitaxel.

13 Oct 2009

Vitrolife and Cellartis extend collaboration in stem cell research

Vitrolife has entered into a new 3-year collaboration agreement with Cellartis AB regarding the development of new products for the culture, handling and differentiation of stem cells. The agreement extends the previous collaboration between the companies.

8 Oct 2009

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Baxter International Inc. today confirmed that the European Commission (EC) has granted marketing authorization for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union.

From Baxter International Inc. 7 Oct 2009

Fully validated assay to detect the presence of Calicivirus 2117 in biological samples

BioReliance Corporation announced today that it has launched a fully validated assay which can sensitively detect the presence of Calicivirus 2117 in biological samples. The test is designed to provide manufacturers of biological therapeutics and other biologically based products the ability to detect this potential contaminant of mammalian cell culture based systems.

7 Oct 2009

Vivaldi receives US patent for live attenuated influenza vaccines

Vivaldi Biosciences Inc. (Vivaldi), a biotechnology company focused on development of vaccines for influenza, today announced that the United States Patent and Trademark Office has issued US Patent 7,588,768 covering live attenuated influenza vaccines (LAIVs) with modifications to the viral NS1 gene, and methods for producing the vaccines in cell culture systems.

6 Oct 2009

EMEA grants positive opinion for Baxter's CELVAPAN H1N1 pandemic vaccine

Baxter International Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) granted its “positive opinion” for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. This positive opinion confirms the acceptability of Baxter’s regulatory submission to obtain final marketing authorization and licensure of the product.

From Baxter International Inc. 3 Oct 2009

New drug test promises to yield quick and effective response for cancer therapy

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 - ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

23 Sep 2009

StemCells pushing forward its SC Proven cell culture product business

StemCells, Inc. (NASDAQ:STEM) today announced organizational initiatives focused on growing its specialty SC Proven® cell culture product business and advancing the development and commercialization of its central nervous system (CNS) cell-based assay platforms for use in drug screening and drug development. These initiatives reflect the Company’s ongoing integration of the operations acquired from Stem Cell Sciences (SCS) Plc in April, and include new personnel appointments and a realignment of activities within the Company’s Cambridge, UK and Palo Alto, California locations.

23 Sep 2009

SEA technology to increase potency of monoclonal antibodies

Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.

23 Sep 2009

Exosomes News and Research

D3 FastPoint L-DFA Influenza A/ Influenza B Virus Identification Kit receives FDA clearance

Anti-viral drug development programs progress successfully, reports NanoViricides

Aethlon Medical establishes ESI as a wholly owned subsidiary

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

Novavax, Avimex and GE Healthcare initiate clinical study of H1N1 VLP influenza vaccine

Bio-Bridge Science receives business license for Bio-Bridge JRS Biosciences (Beijing)

Baxter International announces financial results for third quarter 2009; updates full-year financial outlook

Advanced Projects Group and Cellectricon collaborate to produce the Dynaflow HT patch clamp equipment system

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Researchers discover compounds that show promise as novel treatments for AIDS

International Stem Cell launches human cell culture products into commercial research markets

European Patent Office announces intention to grant patent for Phyton Biotech's methods of producing taxanes

Vitrolife and Cellartis extend collaboration in stem cell research

Baxter receives marketing authorization for CELVAPAN H1N1 pandemic influenza vaccine

Fully validated assay to detect the presence of Calicivirus 2117 in biological samples

Vivaldi receives US patent for live attenuated influenza vaccines

EMEA grants positive opinion for Baxter's CELVAPAN H1N1 pandemic vaccine

New drug test promises to yield quick and effective response for cancer therapy

StemCells pushing forward its SC Proven cell culture product business

SEA technology to increase potency of monoclonal antibodies

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News